US Edition
Published • loading... • Updated
BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
Summary by Laotian Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development. BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution. SUZHOU, China, Feb. 9, 2026 /PRNewswire/ — BioDlink announced that it […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
